Related Experiment Video
Updated: Jun 2, 2026
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
Published on: July 28, 2020
Suppression of soft tissue sarcoma growth by a host defense-like lytic peptide
Lars Steinstraesser1, Jennifer Hauk, Cornelius Schubert
1Laboratory for Wound Healing and Molecular Oncology, Department of Plastic Surgery, BG University Hospital Bergmannsheil, Ruhr University Bochum, Bochum, North Rhine-Westphalia, Germany. Lars.Steinstraesser@rub.de
Background:
Soft tissue sarcoma (STS) is an anatomically and histologically heterogeneous neoplasia that shares a putative mesenchymal cell origin. The treatment with common chemotherapeutics is still unsatisfying because of association with poor response rates. Although evidence is accumulating for potent oncolytic activity of host defense peptides (HDPs), their potential therapeutic use is often limited by poor bioavailability and inactivation in serum. Therefore, we tested the designer host defense-like lytic D,L-amino acid peptide [D]-K3H3L9 on two STS cell lines in vitro and also in an athymic and syngeneic mouse model. In recent studies the peptide could show selectivity against prostate carcinoma cells and also an active state in serum.
Methods:
In vitro the human synovial sarcoma cell line SW982, the murine fibrosarcoma cell line BFS-1 and primary human fibroblasts as a control were exposed to [D]-K3H3L9, a 15mer D,L-amino acid designer HDP. Cell vitality in physiological and acidic conditions (MTT-assay), cell growth (BrdU) and DNA-fragmentation (TUNEL) were investigated. Membrane damage at different time points could be analyzed with LDH assay. An antibody against the tested peptide and recordings using scanning electron microscopy could give an inside in the mode of action. In vivo [D]-K3H3L9 was administered intratumorally in an athymic and syngeneic (immunocompetent) mouse model with SW982 and BFS-1 cells, respectively. After three weeks tumor sections were histologically analyzed.
Results:
The peptide exerts rapid and high significant cytotoxicity and antiproliferating activity against the malignant cell lines, apparently via a membrane disrupting mode of action. The local intratumoral administration of [D]-K3H3L9 in the athymic and syngeneic mice models significantly inhibited tumor progression. The histological analyses of the tumor sections revealed a significant antiproliferative, antiangiogenic activity of the treatment group.
Conclusion:
These findings demonstrate the in vitro and in vivo oncolytic activity of [D]-K3H3L9 in athymic and syngeneic mouse models.
Insights
The novel peptide [D]-K3H3L9 shows significant oncolytic activity against soft tissue sarcoma (STS) cells in vitro and inhibits tumor growth in vivo. This host defense-like peptide offers a promising new therapeutic avenue for STS treatment.
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Background:
- Soft tissue sarcoma (STS) is a heterogeneous cancer with limited treatment options.
- Current chemotherapeutics show poor response rates in STS.
- Host defense peptides (HDPs) exhibit oncolytic potential but face bioavailability challenges.
Purpose of the Study:
- To evaluate the efficacy of the designer HDP [D]-K3H3L9 against STS.
- To investigate the in vitro and in vivo anti-cancer activity of [D]-K3H3L9.
Main Methods:
- In vitro studies used STS cell lines (SW982, BFS-1) and human fibroblasts, assessing cytotoxicity, proliferation, and DNA fragmentation.
- In vivo studies involved intratumoral administration of [D]-K3H3L9 in athymic and syngeneic mouse models.
- Mechanisms of action were explored using assays like LDH and scanning electron microscopy.
Main Results:
- [D]-K3H3L9 demonstrated rapid and significant cytotoxicity and antiproliferative effects on STS cell lines.
- The peptide disrupted cell membranes, leading to cell death.
- Intratumoral administration of [D]-K3H3L9 significantly inhibited tumor progression in both mouse models.
- Histological analysis revealed antiproliferative and antiangiogenic effects.
Conclusions:
- [D]-K3H3L9 exhibits potent in vitro and in vivo oncolytic activity against soft tissue sarcoma.
- The peptide's membrane-disrupting mechanism contributes to its efficacy.
- [D]-K3H3L9 represents a potential therapeutic agent for soft tissue sarcoma.
More Related Videos
Related Concept Videos
02:23Abnormal Proliferation
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:28Cells of the Innate Immune Response
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
01:27Tumor Immunotherapy